Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing small-molecule therapeutics derived from boron chemistry platform. The company’s lead product candidates include tavaborole, an antifungal product candidate in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate that completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis. It also engages in developing GSK2251052, or GSK '052, a systemic antibiotic product candidate in Phase II clinical development for the treatment of infections caused by Gram-negative bacteria; AN8194 for the treatment of an animal health indication; and AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis. The company’s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; and AN2898, a topical anti-inflammatory product candidate in the Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis. It has research, development, and collaboration agreements with GlaxoSmithKline LLC; Eli Lilly and Company; Medicis Pharmaceutical Corporation; and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.